{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:36:51Z","timestamp":1789688211395,"version":"4.0.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"2024 China Industrial Technology Infrastructure Public Service Platform Project","award":["GN2024-31-4700"],"award-info":[{"award-number":["GN2024-31-4700"]}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2024YFA0919904"],"award-info":[{"award-number":["2024YFA0919904"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7252202"],"award-info":[{"award-number":["7252202"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["25JL008"],"award-info":[{"award-number":["25JL008"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300196"],"award-info":[{"award-number":["82300196"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing Municipality","doi-asserted-by":"publisher","award":["CSTB2023NSCQ-MSX0262"],"award-info":[{"award-number":["CSTB2023NSCQ-MSX0262"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chongqing Young Medical Talents Program","award":["YXQN2025024"],"award-info":[{"award-number":["YXQN2025024"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08191-1","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:57:03Z","timestamp":1777521423000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["GD3s-mediated lipid metabolism reprograming promotes proliferation and metastasis of melanoma"],"prefix":"10.1186","volume":"24","author":[{"given":"Jinyi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanhua","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8367-0787","authenticated-orcid":false,"given":"Jinhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"issue":"3","key":"8191_CR1","first-page":"28","volume":"20","author":"SS Yde","year":"2018","unstructured":"Yde SS, Sjoegren P, Heje M, Stolle LB. Mucosal Melanoma: Literature Rev Curr Oncol Rep. 2018;20(3):28.","journal-title":"Mucosal Melanoma: Literature Rev Curr Oncol Rep"},{"key":"8191_CR2","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1146\/annurev.me.44.020193.002003","volume":"44","author":"JA Sanchez","year":"1993","unstructured":"Sanchez JA, Robinson WA. Malignant melanoma. Annu Rev Med. 1993;44:335\u201342.","journal-title":"Annu Rev Med"},{"issue":"2","key":"8191_CR3","doi-asserted-by":"publisher","first-page":"e330","DOI":"10.1097\/PRS.0000000000002367","volume":"138","author":"SN Pavri","year":"2016","unstructured":"Pavri SN, Clune J, Ariyan S, Narayan D. Malignant Melanoma: Beyond the Basics. Plast Reconstr Surg. 2016;138(2):e330\u201340.","journal-title":"Plast Reconstr Surg"},{"issue":"11","key":"8191_CR4","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1080\/15384047.2019.1640032","volume":"20","author":"LE Davis","year":"2019","unstructured":"Davis LE, Shalin SC, Tackett AJ. Current state of melanoma diagnosis and treatment. Cancer Biol Ther. 2019;20(11):1366\u201379.","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"8191_CR5","first-page":"275","volume":"52","author":"H Rahmann","year":"1982","unstructured":"Rahmann H, Probst W, M\u00fchleisen M. Gangliosides and synaptic transmission. Japanese J experimental Med. 1982;52(6):275\u201386.","journal-title":"Japanese J experimental Med"},{"issue":"1","key":"8191_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1432-1033.1979.tb12866.x","volume":"94","author":"J Portoukalian","year":"1979","unstructured":"Portoukalian J, Zwingelstein G, Dor\u00e9 JF. Lipid composition of human malignant melanoma tumors at various levels of malignant growth. Eur J Biochem. 1979;94(1):19\u201323.","journal-title":"Eur J Biochem"},{"issue":"8","key":"8191_CR7","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1002\/1878-0261.12702","volume":"14","author":"RI Ramos","year":"2020","unstructured":"Ramos RI, Bustos MA, Wu J, Jones P, Chang SC, Kiyohara E, Tran K, Zhang X, Stern SL, Izraely S, Sagi-Assif O, Witz IP, Davies MA, Mills GB, Kelly DF, Irie RF, Hoon DSB. Upregulation of cell surface GD3 ganglioside phenotype is associated with human melanoma brain metastasis. Mol Oncol. 2020;14(8):1760\u201378.","journal-title":"Mol Oncol"},{"issue":"23","key":"8191_CR8","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1038\/onc.2014.245","volume":"34","author":"TR Sarkar","year":"2015","unstructured":"Sarkar TR, Battula VL, Werden SJ, Vijay GV, Ramirez-Pe\u00f1a EQ, Taube JH, Chang JT, Miura N, Porter W, Sphyris N, Andreeff M, Mani SA. GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer. Oncogene. 2015;34(23):2958\u201367.","journal-title":"Oncogene"},{"issue":"4","key":"8191_CR9","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1007\/s12094-020-02484-7","volume":"23","author":"H Wan","year":"2021","unstructured":"Wan H, Li Z, Wang H, Cai F, Wang L, Akt\/mTOR FAK. Clin translational oncology: official publication Federation Span Oncol Soc Natl Cancer Inst Mexico. 2021;23(4):902\u201310.","journal-title":"Clin translational oncology: official publication Federation Span Oncol Soc Natl Cancer Inst Mexico"},{"issue":"5","key":"8191_CR10","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.apsb.2018.07.009","volume":"8","author":"J Liu","year":"2018","unstructured":"Liu J, Zheng X, Pang X, Li L, Wang J, Yang C, Du G. Ganglioside GD3 synthase (GD3S), a novel cancer drug target. Acta Pharm Sinica B. 2018;8(5):713\u201320.","journal-title":"Acta Pharm Sinica B"},{"issue":"12","key":"8191_CR11","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3858\/emm.2010.42.12.088","volume":"42","author":"HY Kwon","year":"2010","unstructured":"Kwon HY, Kim SJ, Kim CH, Son SW, Kim KS, Lee JH, Do SI, Lee YC. Triptolide downregulates human GD3 synthase (hST8Sia I) gene expression in SK-MEL-2 human melanoma cells. Exp Mol Med. 2010;42(12):849\u201355.","journal-title":"Exp Mol Med"},{"issue":"23","key":"8191_CR12","doi-asserted-by":"publisher","first-page":"723","DOI":"10.21037\/atm.2019.12.23","volume":"7","author":"W Li","year":"2019","unstructured":"Li W, Zheng X, Ren L, Fu W, Liu J, Xv J, Liu S, Wang J, Du G. Epigenetic hypomethylation and upregulation of GD3s in triple negative breast cancer. Annals translational Med. 2019;7(23):723.","journal-title":"Annals translational Med"},{"issue":"6","key":"8191_CR13","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/BF00731251","volume":"12","author":"S Yamashiro","year":"1995","unstructured":"Yamashiro S, Okada M, Haraguchi M, Furukawa K, Lloyd KO, Shiku H, Furukawa K. Expression of alpha 2,8-sialyltransferase (GD3 synthase) gene in human cancer cell lines: high level expression in melanomas and up-regulation in activated T lymphocytes. Glycoconj J. 1995;12(6):894\u2013900.","journal-title":"Glycoconj J"},{"issue":"11","key":"8191_CR14","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1038\/s41401-022-00917-3","volume":"43","author":"XJ Zheng","year":"2022","unstructured":"Zheng XJ, Chen WL, Yi J, Li W, Liu JY, Fu WQ, Ren LW, Li S, Ge BB, Yang YH, Zhang YZ, Yang H, Du GH, Wang Y, Wang JH. Apolipoprotein C1 promotes glioblastoma tumorigenesis by reducing KEAP1\/NRF2 and CBS-regulated ferroptosis. Acta Pharmacol Sin. 2022;43(11):2977\u201392.","journal-title":"Acta Pharmacol Sin"},{"key":"8191_CR15","first-page":"e51998","volume":"92","author":"S Borowicz","year":"2014","unstructured":"Borowicz S, Van Scoyk M, Avasarala S, Karuppusamy Rathinam MK, Tauler J, Bikkavilli RK, Winn RA. The soft agar colony formation assay. J visualized experiments: JoVE. 2014;92:e51998.","journal-title":"J visualized experiments: JoVE"},{"issue":"1","key":"8191_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40880-018-0301-4","volume":"38","author":"C Cheng","year":"2018","unstructured":"Cheng C, Geng F, Cheng X, Guo D. Lipid metabolism reprogramming and its potential targets in cancer. Cancer Commun (London England). 2018;38(1):27.","journal-title":"Cancer Commun (London England)"},{"issue":"5","key":"8191_CR17","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.ccell.2021.01.011","volume":"39","author":"EE Patton","year":"2021","unstructured":"Patton EE, Mueller KL, Adams DJ, Anandasabapathy N, Aplin AE, Bertolotto C, Bosenberg M, Ceol CJ, Burd CE, Chi P, Herlyn M, Holmen SL, Karreth FA, Kaufman CK, Khan S, Kobold S, Leucci E, Levy C, Lombard DB, Lund AW, Marie KL, Marine JC, Marais R, McMahon M, Robles-Espinoza CD, Ronai ZA, Samuels Y, Soengas MS, Villanueva J, Weeraratna AT, White RM, Yeh I, Zhu J, Zon LI, Hurlbert MS, Merlino G. Melanoma models for the next generation of therapies. Cancer Cell. 2021;39(5):610\u201331.","journal-title":"Cancer Cell"},{"key":"8191_CR18","doi-asserted-by":"crossref","unstructured":"Klemen ND, Wang M, Rubinstein JC, Olino K, Clune J, Ariyan S, Cha C, Weiss SA, Kluger HM, Sznol M. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma. J Immunother Cancer. 2020;8(1).","DOI":"10.1136\/jitc-2019-000341"},{"issue":"5","key":"8191_CR19","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"issue":"3","key":"8191_CR20","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","volume":"41","author":"MV Liberti","year":"2016","unstructured":"Liberti MV, Locasale JW. The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem Sci. 2016;41(3):211\u20138.","journal-title":"Trends Biochem Sci"},{"issue":"8","key":"8191_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.4331\/wjbc.v3.i8.167","volume":"3","author":"F Zhang","year":"2012","unstructured":"Zhang F, Du G. Dysregulated lipid metabolism in cancer. World J Biol Chem. 2012;3(8):167\u201374.","journal-title":"World J Biol Chem"},{"issue":"1","key":"8191_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cmet.2007.10.002","volume":"7","author":"RJ DeBerardinis","year":"2008","unstructured":"DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metabol. 2008;7(1):11\u201320.","journal-title":"Cell Metabol"},{"issue":"2","key":"8191_CR23","doi-asserted-by":"publisher","first-page":"156","DOI":"10.2174\/1389450115666141224125117","volume":"16","author":"AD Khwairakpam","year":"2015","unstructured":"Khwairakpam AD, Shyamananda MS, Sailo BL, Rathnakaram SR, Padmavathi G, Kotoky J, Kunnumakkara AB. ATP citrate lyase (ACLY): a promising target for cancer prevention and treatment. Curr Drug Targets. 2015;16(2):156\u201363.","journal-title":"Curr Drug Targets"},{"issue":"11","key":"8191_CR24","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1080\/14728222.2017.1381087","volume":"21","author":"JA Menendez","year":"2017","unstructured":"Menendez JA, Lupu R. Fatty acid synthase (FASN) as a therapeutic target in breast cancer. Expert Opin Ther Targets. 2017;21(11):1001\u201316.","journal-title":"Expert Opin Ther Targets"},{"key":"8191_CR25","doi-asserted-by":"crossref","unstructured":"Stamatakos S, Beretta GL, Vergani E, Dugo M, Corno C, Corna E, Tinelli S, Frigerio S, Ciusani E, Rodolfo M, Perego P, Gatti L. Deregulated FASN expression in BRAF inhibitor-resistant melanoma cells unveils new targets for drug combinations. Cancers. 2021;13(9).","DOI":"10.3390\/cancers13092284"},{"issue":"1","key":"8191_CR26","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/s13046-019-1391-9","volume":"38","author":"J Wen","year":"2019","unstructured":"Wen J, Min X, Shen M, Hua Q, Han Y, Zhao L, Liu L, Huang G, Liu J, Zhao X. ACLY facilitates colon cancer cell metastasis by CTNNB1. J experimental Clin cancer research: CR. 2019;38(1):401.","journal-title":"J experimental Clin cancer research: CR"},{"issue":"1","key":"8191_CR27","doi-asserted-by":"publisher","first-page":"10369","DOI":"10.1038\/s41598-019-46594-x","volume":"9","author":"S Wu","year":"2019","unstructured":"Wu S, N\u00e4\u00e4r AM. SREBP1-dependent de novo fatty acid synthesis gene expression is elevated in malignant melanoma and represents a cellular survival trait. Sci Rep. 2019;9(1):10369.","journal-title":"Sci Rep"},{"issue":"4","key":"8191_CR28","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cmet.2012.09.002","volume":"16","author":"W Shao","year":"2012","unstructured":"Shao W, Espenshade PJ. Expanding roles for SREBP in metabolism. Cell Metabol. 2012;16(4):414\u20139.","journal-title":"Cell Metabol"},{"issue":"9","key":"8191_CR29","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1172\/JCI0215593","volume":"109","author":"JD Horton","year":"2002","unstructured":"Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Investig. 2002;109(9):1125\u201331.","journal-title":"J Clin Investig"},{"issue":"6","key":"8191_CR30","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1053\/j.gastro.2004.09.049","volume":"127","author":"M You","year":"2004","unstructured":"You M, Matsumoto M, Pacold CM, Cho WK, Crabb DW. The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology. 2004;127(6):1798\u2013808.","journal-title":"Gastroenterology"},{"issue":"4","key":"8191_CR31","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1039\/C9FO02471A","volume":"11","author":"QA Han","year":"2020","unstructured":"Han QA, Su D, Shi C, Liu P, Wang Y, Zhu B, Xia X. Urolithin A attenuated ox-LDL-induced cholesterol accumulation in macrophages partly through regulating miR-33a and ERK\/AMPK\/SREBP1 signaling pathways. Food Funct. 2020;11(4):3432\u201340.","journal-title":"Food Funct"},{"key":"8191_CR32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.canlet.2017.05.002","volume":"401","author":"Q Liu","year":"2017","unstructured":"Liu Q, Luo Q, Halim A, Song G. Targeting lipid metabolism of cancer cells: A promising therapeutic strategy for cancer. Cancer Lett. 2017;401:39\u201345.","journal-title":"Cancer Lett"},{"issue":"2","key":"8191_CR33","doi-asserted-by":"publisher","first-page":"171","DOI":"10.7150\/ijbs.7357","volume":"10","author":"J Li","year":"2014","unstructured":"Li J, Dong L, Wei D, Wang X, Zhang S, Li H. Fatty acid synthase mediates the epithelial-mesenchymal transition of breast cancer cells. Int J Biol Sci. 2014;10(2):171\u201380.","journal-title":"Int J Biol Sci"},{"issue":"2","key":"8191_CR34","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.yexcr.2019.04.006","volume":"379","author":"ZG Zhang","year":"2019","unstructured":"Zhang ZG, Zhang HS, Sun HL, Liu HY, Liu MY, Zhou Z. KDM5B promotes breast cancer cell proliferation and migration via AMPK-mediated lipid metabolism reprogramming. Exp Cell Res. 2019;379(2):182\u201390.","journal-title":"Exp Cell Res"},{"issue":"4","key":"8191_CR35","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.gendis.2020.01.015","volume":"8","author":"V Adorno-Cruz","year":"2021","unstructured":"Adorno-Cruz V, Hoffmann AD, Liu X, Dashzeveg NK, Taftaf R, Wray B, Keri RA, Liu H. ITGA2 promotes expression of ACLY and CCND1 in enhancing breast cancer stemness and metastasis. Genes Dis. 2021;8(4):493\u2013508.","journal-title":"Genes Dis"},{"issue":"5","key":"8191_CR36","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s11684-021-0830-0","volume":"15","author":"J Zhang","year":"2021","unstructured":"Zhang J, Song Y, Shi Q, Fu L. Research progress on FASN and MGLL in the regulation of abnormal lipid metabolism and the relationship between tumor invasion and metastasis. Front Med. 2021;15(5):649\u201356.","journal-title":"Front Med"},{"issue":"6","key":"8191_CR37","doi-asserted-by":"publisher","first-page":"e359","DOI":"10.1097\/MPH.0000000000001416","volume":"41","author":"A Jayanthan","year":"2019","unstructured":"Jayanthan A, Hofmann B, Meier-Stephenson V, Perinpanayagam M, Dunn SE, Boklan J, Trippett TM, Truong TH, Narendran A. Targeted Polo-like Kinase Inhibition Combined With Aurora Kinase Inhibition in Pediatric Acute Leukemia Cells. J Pediatr Hematol Oncol. 2019;41(6):e359\u201370.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"8191_CR38","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1365-2141.2010.08248.x","volume":"150","author":"X Wang","year":"2010","unstructured":"Wang X, Sinn AL, Pollok K, Sandusky G, Zhang S, Chen L, Liang J, Crean CD, Suvannasankha A, Abonour R, Sidor C, Bray MR, Farag SS. Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma. Br J Haematol. 2010;150(3):313\u201325.","journal-title":"Br J Haematol"},{"issue":"1","key":"8191_CR39","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1158\/1535-7163.MCT-10-0574","volume":"10","author":"GC Fletcher","year":"2011","unstructured":"Fletcher GC, Brokx RD, Denny TA, Hembrough TA, Plum SM, Fogler WE, Sidor CF, Bray MR. ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action. Mol Cancer Ther. 2011;10(1):126\u201337.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"8191_CR40","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1182\/blood-2013-03-488072","volume":"122","author":"M W\u00f6lfl","year":"2013","unstructured":"W\u00f6lfl M, Schwinn S, Yoo YE, Re\u00df ML, Braun M, Chopra M, Schreiber SC, Ayala VI, Ohlen C, Eyrich M, Beilhack A, Schlegel PG. Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis. Blood. 2013;122(7):1203\u201313.","journal-title":"Blood"},{"key":"8191_CR41","doi-asserted-by":"crossref","unstructured":"Matulonis U.A., Lee J, Lasonde B, Tew WP, Yehwalashet A, Matei D, Behbakht K, Grothusen J, Fleming G, Lee NK, Arnott J, Bray MR, Fletcher G, Brokx RD, Castonguay V, Mackay H, Sidor CF, Oza AM. ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer. Eur J cancer (Oxford England: 1990). 2013;49(1):121\u201331.","DOI":"10.1016\/j.ejca.2012.07.020"},{"issue":"24","key":"8191_CR42","doi-asserted-by":"publisher","first-page":"6168","DOI":"10.1158\/1078-0432.CCR-18-1244","volume":"24","author":"S Lheureux","year":"2018","unstructured":"Lheureux S, Tinker A, Clarke B, Ghatage P, Welch S, Weberpals JI, Dhani NC, Butler MO, Tonkin K, Tan Q, Tan DSP, Brooks K, Ramsahai J, Wang L, Pham NA, Shaw PA, Tsao MS, Garg S, Stockley T, Oza AM. A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium. Clin cancer research: official J Am Association Cancer Res. 2018;24(24):6168\u201374.","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"issue":"12","key":"8191_CR43","doi-asserted-by":"publisher","first-page":"e1837","DOI":"10.1634\/theoncologist.2020-0093","volume":"25","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Mayer R, Venook AP, O\u2019Neill AF, Beg MS, LaQuaglia M, Kingham PT, Kobos R, Basturk O, Brennan C, Yopp A, Harding JJ, Leong S, Crown J, Hoti E, Leonard G, Ly M, Bradley M, Valentino E, Markowitz D, Zukiwski A, Ren K, Gordan JD. Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma. Oncologist. 2020;25(12):e1837\u201345.","journal-title":"Oncologist"},{"issue":"1","key":"8191_CR44","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13058-018-1014-y","volume":"20","author":"JR Diamond","year":"2018","unstructured":"Diamond JR, Eckhardt SG, Pitts TM, van Bokhoven A, Aisner D, Gustafson DL, Capasso A, Sams S, Kabos P, Zolman K, Colvin T, Elias AD, Storniolo AM, Schneider BP, Gao D, Tentler JJ, Borges VF, Miller KD. A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer. Breast cancer research: BCR. 2018;20(1):82.","journal-title":"Breast cancer research: BCR"},{"issue":"1","key":"8191_CR45","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1158\/1078-0432.CCR-12-1611","volume":"19","author":"JR Diamond","year":"2013","unstructured":"Diamond JR, Eckhardt SG, Tan AC, Newton TP, Selby HM, Brunkow KL, Kachaeva MI, Varella-Garcia M, Pitts TM, Bray MR, Fletcher GC, Tentler JJ. Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models. Clin cancer research: official J Am Association Cancer Res. 2013;19(1):291\u2013303.","journal-title":"Clin cancer research: official J Am Association Cancer Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08191-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08191-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08191-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T02:04:06Z","timestamp":1781748246000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08191-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8191"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08191-1","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"21 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was approved by the Institutional Review Board (IRB) of John Wayne Cancer Institute. All participants provided informed consent prior to the study. The animal study protocol was approved by the Animal Care and Use Committee (ACUC) of Institute of Materia Medica, CAMS & PUMC. The study adhered to the guidelines set by the committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that there is no conflict of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"780"}}